The biotechnology sector, as measured by the XBI ETF, experienced a downturn of -2.04% in the current session. This move appears to be driven by a combination of broad market negativity, particularly in growth and technology-related sectors, and significant declines in individual biotech stocks. AnaptysBio (ANAB), a component of the XBI, saw its shares fall over 6%. This decline follows a period of strong performance for the biotech sector, suggesting that profit-taking may also be a contributing factor amidst a risk-off market sentiment.